Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART

AIDS

Volumn 20, Issue 9, 2006, Pages 1327-1329

  Makinson, Alain ^a,b   Masquelier, Bernard ^c   Taieb, Audrey ^d   Peytavin, Gilles ^a   Waldner Combernoux, Anne ^e   Collin, Gilles ^a   Chêne, Genevieve ^c   Brun Vézinet, Françoise ^a   Raffi, François ^f   Le Moing, Vincent ^b   Leport, Catherine ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DNA SEQUENCE; GENE IDENTIFICATION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOP CODON; TREATMENT FAILURE; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CODON, TERMINATOR; COHORT STUDIES; DNA, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33745838653     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000232242.51286.7b     Document Type: Article

References (13)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
2. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-29.
3. Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, et al. Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study. J Infect Dis 2002; 186:1503-1507.
4. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids 2001; 15:71-75.
5. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation. Bioinformatics 2000; 16:400-401.
6. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-413.
7. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-1260.
8. Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187:38-46.
9. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G → A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 2005; 79:1975-1980.
10. Yedavalli VR, Ahmad N. Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 2001; 17:911-923.
11. Koulinska IN, Chaplin B, Mwakagile D, Essex M, Renjifo B. Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses 2003; 19:1115-1123.
12. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena NK. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 2003; 312:135-150.
13. Goff SP. Death by deamination: a novel host restriction system for HIV-1. Cell 2003; 114:281-283.